An Open-label, Pharmacokinetic Study of Lenalidomide (Revlimid) and High-dose Dexamethasone Induction Therapy in Previously Untreated Multiple Myeloma Patients With Various Degrees of Renal Dysfunction - Validation of Official Dosing Guidelines for Renal Failure
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2018
At a glance
- Drugs Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Pharmacokinetics
- 27 Dec 2017 Status changed from active, no longer recruiting to completed.
- 19 Sep 2017 Planned End Date changed from 1 Aug 2017 to 31 Dec 2018.
- 19 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 31 Dec 2017.